Islet amyloid in type 2 (non-insulin-dependent) diabetes

APMIS

Volumn 104, Issue 1, 1996, Pages 12-18

  Clark, A ^a,b   Charge S B P ^a   Badman, M K ^b   De Koning, E J P ^a,b  

^a RADCLIFFE INFIRMARY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Amyloid; Diabetes; Islet amyloid polypeptide; Islets of Langerhans; Toxicity; Transgenic mice

Indexed keywords

AMYLOID;

ANIMAL CELL; CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOELECTRON MICROSCOPY; IMMUNOGOLD STAINING; IMMUNOHISTOCHEMISTRY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

EID: 0029926036     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1996.tb00680.x     Document Type: Review

References (47)

1. Bajaj, J. S. & Subba Rao, G.: Malnutrition-related diabetes mellitus. In: Krall, L. P. (Ed.): World Book of Diabetes in Practise 3. Elsevier Science Publishing NY. 1988.
2. Betzholtz, C., Christmanson, L., Engström, U., Rorsman, F., Jordan, K., O'Brien, T. D., Murtaugh, M., Johnson, K. H. & Westermark, P.: Structure of cat islet amyloid polypeptide and identification of amino acid residues of potential significance for islet amyloid formation. Diabetes 39: 118-122, 1990.
3. Bretherton-Watt, D., Gilbey, S. G., Ghatei, M. A., Beacham, J., Machae, A. D. & Bloom, S. R.: Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J. Clin. Endocrinol. 74: 1032-1035, 1992.
4. Butler, P. C., Chou, J., Carter, W. B., Wang, Y.-N., Bu, B.-H., Chang, D. Chang, J.-K. & Rizza, R. A.: Effects of meal ingestion on plasma amylin concentration in NIDDM and non-diabetic humans. Diabetes 39: 752-756, 1990.
5. Chargé, S. B. P., de Koning, E. J. P. & Clark, A.: The effect of PH and insulin on fibrillogenesis of islet amyloid polypeptide in vitro. Biochemistry 34: 14588-14593, 1995.
6. Clark, A.: Islet amyloid: an enigma of Type 2 diabetes. Diabetes Metab. Rev. 8: 117-132, 1992.
7. Clark, A., Cooper, G. J. S., Lewis, C. E., Morris, J. F., Willis, A. C., Reid, K. B. M. & Turner, R. C.: Islet amyloid formed from diabetes associated peptide may be pathogenic in type 2 diabetes. Lancet 2: 231-234, 1987.
8. Clark, A., Wells, C. A., Buley, I. D., Cruickshank, J. K., Vanhegan, R. I., Matthews, D. R., Cooper, G. J. S., Holman, R. R. & Turner, R. C.: Islet amyloid, increased A-cells, reduced β-cells and exocrine fibrosis: quantitative changes in the pancreas in Type 2 diabetes. Diabetes Research 9: 151-160, 1988.
9. Clark, A., Saad, M. F., Nezzer, T., Uren, C., Knowler, W. C., Bennett, P. H. & Turner, R. C.: Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33: 285-289, 1990.
10. Clark, A., Lloyd, J., Novials, A., Hutton, J. C. & Morris, J. F.: Localisation of islet amyloid polypeptide and its carboxy-terminal flanking peptide in islets of diabetic man and monkey. Diabetologia 34: 449-451, 1991.
11. Clark, A., Badman, M. K., Lowndes, S. A. & Morris, J. F.: Aggregated human islet amyloid polypeptide is not cytotoxic to mouse islets in vitro. Diabetologia 38: Suppl. 1 A91, 1995.
12. Cook, J. T. E., Patel, P., Clark, A., Höppener, J. W. M., Lips, C. J. M., Mosselman, S., O'Rahilly, S. P., Page, R. C., Wainscoat, J. S. & Turner, R. C.: Non-linkage of the islet amyloid polypeptide gene with type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 34: 103-108, 1991.
13. Cooper, G. J. S., Leighton, B., Dimitriadis, G. D., Parry-Billings, M., Kowalchuk, J. M., Howland, K., Rothbard, J. B., Willis, A. C. & Reid, K. B. M.: Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc. Natl. Acad. Sci. 85: 7763-7766, 1988.
14. de Koning, E. J. P., Bodkin, N. L., Hansen, B. C. & Clark, A.: Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in B-cell population. Diabetologia 36: 378-384, 1993.
15. de Koning, E. J. P., Höppener, J. W. M., Verbeek, J. S., Oosterwijk, C., van Hulst, K. L., Baker, C. A., Lips, C. J. M., Morris, J. F. & Clark, A.: Human islet amyloid polypeptide accumulates at similar sites in islets of transgenic mice and humans. Diabetes 43: 640-644, 1994a.
16. de Koning, E. J. P., Morris, E. R., Hofhuis, F. M. A., Posthuma, G., Höppener, J. W. M., Morris, J. F., Capel, P. J. A., Clark, A. & Verbeek, J. S.: Intraand extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide. Proc. Natl. Acad. Sci. USA 91: 8467-8471, 1994b.
17. de Koning, E. J. P., Fleming, K. A., Gray, D. W. R., Clark, A.: High prevalence of pancreatic islet amyloid in patients with end-stage renal failure on dialysis treatment. J. Pathol. 175: 253-258, 1995a.
18. de Koning, E. J. P., MacArthur, D. L. A., Verbeek, J. S., Hofhuis, F. M. A., Morris, J. F., Capel, P. & Clark, A.: Amyloidosis in islets of transgenic mice is not cytotoxic and is related to secretion of islet amyloid polypeptide. Diabetologia 38: Suppl. 1, A91, 1995b.
19. Eriksson, J., Nakazato, M., Miyazato, M., Shiomi, K. & Groop, L. Islet amyloid polypeptide plasma concentration in individuals at increased risk of developing Type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 35: 291-293, 1992.
20. Hattersley, A., Turner, R. C., Permutt, M. A., Patel, P., Tanizawa, M. D., Chiu, K. C., O'Rahilly, S., Watkins, P. & Wainscoat, J. S.: Type 2 diabetes is linked to the glucokinase gene in a large pedigree. Lancet 339: 1307-1310, 1994.
21. Höppener, J. W. M., Verbeek, J. S., de Koning, E. J. P., Oosterwijk, C, van Hulst, K. L., Visser-Vernoy, H. J., Hofhuis, F. M. A., van Galen, S., Berends, M. J. H., Hackeng, W. H. L., Jansz, H. S., Morris, J. F., Clark, A., Capel, P. J. A. & Lips, C. J. M.: Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: lysosomal localisation of human islet amyloid polypeptide and lack of marked hyperglycaemia or hyperinsulinaemia. Diabetologia 36: 1258-1265, 1993.
22. Howard, C. F.: Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29: 301-306, 1986.
23. Hutton, J. C.: The insulin secretory granule. Diabetologia 32: 271-281, 1989.
24. Iannucci, A., Mukai, K., Johnson, D. & Burke, B.: Endocrine pancreas in cystic fibrosis: an immunohistochemical study. Hum. Pathol. 15: 278-284, 1984.
25. Kassir, A. A., Upadhyay, A. K., Lim, T. J., Moossa, A. R. & Olefsky, J. M.: Lack of effect of islet amyloid polypeptide in causing insulin resistance in conscious dogs during euglycemic clamp studies. Diabetes 40: 998-1004, 1991.
26. Lorenzo, A., Razzaboni, B., Weir, G. C. & Yankner, B. A.: Pancreatic islet cell toxicity of amylin associated with type 2 diabetes mellitus. Nature 368: 756-760, 1994.
27. Ludvik, B., Berzlanovich, A., Hartter, E., Lell, B., Prager, R. & Graf, H.: Increased amylin levels in patients on chronic haemodialysis. Nephrol. Dial. Transplant. 8: 694-695A, 1991.
28. Ludvik, B., Clodi, M., Kautzky-Willer, A., Capek, M., Hartter, E., Pacini, G. & Prager, R.: Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 36: 84-87, 1993.
29. Nishi, M., Chau, S. J., Nagamatsu, S., Bell, G. I & Steiner, D. F.: Conservation of the sequence of islet amyloid polypeptide in five mammals is consistent with its putative role as an islet hormone. Proc. Natl. Acad. Sci. USA 86: 5738-5742, 1989.
30. Nishi, M., Bell, G. I. & Steiner, D. F.: Islet amyloid polypeptide amylin: no evidence of an abnormal precursor sequence in 25 type 2 non-insulin-dependent diabetic patients. Diabetologia 33: 628-630, 1990.
31. O'Brien, T. D., Harden, D. W., Johnson, K. H. & Fletcher, T. F.: Immunohistochemical morphometry of pancreatic endocrine cells in diabetic normoglycaemic glucose-intolerant and normal cats. J. Comp. Pathol. 96: 357-369, 1986.
32. O'Brien, T. D., Rizza, R. A., Carney, J. A. & Butler, P. C.: Islet amyloidosis in a patient with chronic massive insulin resistance due to antiinsulin receptor antibodies. J. Clin. Endocrin. Metab. 79: 290-292, 1994.
33. Opie, E.: The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islets of Langerhans. J. Exp. Med. 5: 527-540, 1901.
34. Porte, D. & Kahn, S. E.: Hyperproinsulinaemia and amyloid in NIDDM: Clues to etiology of islet β-cell dysfunction. Diabetes 38: 1333-1336, 1989.
35. Saito, K., Yaginuma, N. & Takahashi, T.: Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and non-diabetic subjects. Tohoku J. Exp. Med. 129: 273-283, 1979.
36. Sanke, T., Hanabusa, T., Nakamo, Y., Oki, C., Okai, K., Nishimura, S., Kondo, M. & Nanjo, K.: Plasma islet amyloid polypeptide (Amylin): levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34: 129-132, 1991.
37. Schneider, H. M., Storkel, S. & Will, W.: Das Amyloid der Langerhansschen Inseln und seine Beziehung zum Diabetes Mellitus. Dtsch. med. Wschr. 105: 1143-1147, 1980.
38. Vishwanathan, K. A., Bazaz-Malik, G., Dandekar J. & Vaishnava, O.: A qualitative and quantitative histological study of the islets of Langerhans in diabetes mellitus. Indian J. Med. Sci. 26: 807-812, 1972.
39. Westermark, P.: Fine structure of the islets of Langerhans in insular amyloidosis. Virchows Arch. Abt. A Path. Anat. 359: 1-18, 1973.
40. Westermark, P. & Grimelius, L.: The pancreatic islet cell in insular amyloidosis in human diabetic and non-diabetic islets. Acta Path. Microbiol. Scand., Section A, 81: 291-300, 1973.
41. Westermark, P., Wernstedt, C., Wilander, E., Hayden, D. W., O'Brien, T. D. & Johnson, K. H.: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl. Acad. Sci. USA 84: 3881-3885, 1987.
42. Westermark, P., Engström, U., Westermark, G. T., Johnson, K. H., Permerth, J. & Betsholtz, C. Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diab. Res. Clin. Pract. 7: 219-226, 1989.
43. Westermark, P., Engström, U., Johnson, K. H., Westermark, G. T. & Betzholtz, C.: Islet amyloid polypeptide. Pinpointing amino acid residues linked to amyloid fibril formation. Proc. Natl. Acad. Sci. USA 87: 5036-5040, 1990.
44. Wilding, J. P. H., Khandan-Nia, N., Gilbey, S. G., Bennet, W. M., Beacham, J., Ghatei, M. A. & Bloom, S. R.: Amylin does not affect insulin sensitivity in humans. Diabetologia 36 (Suppl. 1): A135, 1993.
45. Wright, A. W.: Hyaline degeneration of the islets of Langerhans in non-diabetics. Amer. J. Pathol. 3: 461-482, 1927.
46. Yajnik, C. S., Shelgikar, K. M., Sahasrabudhe, R. A., Naik, S. S., Pai, V. R., Alberti, K. G. M. M., Hockaday, T. D. R., Datrak, A. & Dandona, P. The spectrum of pancreatic exocrine and endocrine (beta-cell), function in tropical calcific pancreatitis. Diabetologia 33: 417-442, 1990.
47. Young, A. A., Wang, M.-W. & Cooper, G. J. S.: Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS letters 291: 101-104, 1991.